Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

Similar articles for PubMed (Select 18536095)

1.

Abacavir hypersensitivity.

Abel S, Paturel L, Cabié A.

N Engl J Med. 2008 Jun 5;358(23):2515; author reply 2515-6. No abstract available.

PMID:
18536095
2.

Abacavir hypersensitivity.

Vandekerckhove L, Blot S, Vogelaers D.

N Engl J Med. 2008 Jun 5;358(23):2514-5; author reply 2515-6. doi: 10.1056/NEJMc080541. No abstract available.

3.

Current trends in screening across ethnicities for hypersensitivity to abacavir.

Rodriguez-Nóvoa S, Soriano V.

Pharmacogenomics. 2008 Oct;9(10):1531-41. doi: 10.2217/14622416.9.10.1531.

PMID:
18855539
4.

HLA-B*5701 screening for hypersensitivity to abacavir.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team.

N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.

5.

The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.

Airo P, Scarsi M, Malagoli A, Carella G, Izzo I, Carosi G, Torti C.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):361-2. doi: 10.1097/QAI.0b013e3181aa1382. No abstract available.

PMID:
19553774
6.

Labeling changes for abacavir.

[No authors listed]

AIDS Patient Care STDS. 2008 Aug;22(8):683-4. doi: 10.1089/apc.2008.9949. No abstract available.

PMID:
18721055
7.

Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.

Waters LJ, Mandalia S, Gazzard B, Nelson M.

AIDS. 2007 Nov 30;21(18):2533-4.

PMID:
18025891
8.

Uncertainties of routine HLA B*5701 testing in black African HIV cohorts in the UK.

Sadiq ST, Pakianathan M.

Sex Transm Infect. 2007 Jun;83(3):181-2. Epub 2006 Nov 10. No abstract available.

9.

Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.

Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M.

Pharmacogenetics. 2004 Jun;14(6):335-42.

PMID:
15247625
10.

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.

Chui CK, Brumme ZL, Brumme CJ, Yip B, Phillips EJ, Montaner JS, Harrigan PR.

Clin Infect Dis. 2007 Jun 1;44(11):1503-8. Epub 2007 Apr 18.

11.

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT.

Lancet. 2002 Mar 2;359(9308):727-32.

PMID:
11888582
12.

Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.

Giorgini S, Martinelli C, Tognetti L, Carocci A, Giuntini R, Mastronardi V, Torricelli F, Leoncini F, Lotti T.

Dermatol Ther. 2011 Nov-Dec;24(6):591-4. doi: 10.1111/j.1529-8019.2012.01409.x.

PMID:
22515676
13.

Abacavir hypersensitivity reaction predicted by genetic test.

[No authors listed]

AIDS Treat News. 2004 Mar 26;(399):6.

PMID:
15199868
14.

Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients.

Parczewski M, Leszczyszyn-Pynka M, Wnuk A, Urbañska A, Fuksiñska K, Bander D, Boroñ-Kaczmarska A.

HIV Med. 2010 May;11(5):345-8. doi: 10.1111/j.1468-1293.2009.00787.x. Epub 2010 Jan 11.

PMID:
20070406
15.

Successful implementation of a national HLA-B*5701 genetic testing service in Canada.

Lalonde RG, Thomas R, Rachlis A, Gill MJ, Roger M, Angel JB, Smith G, Higgins N, Trottier B.

Tissue Antigens. 2010 Jan;75(1):12-8. doi: 10.1111/j.1399-0039.2009.01383.x. Epub 2009 Oct 15.

PMID:
19843279
16.

HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.

Dvali N, Chkhartishvili N, Sharvadze L, Karchava M, Tsertsvadze T.

Georgian Med News. 2010 Dec;(189):16-20.

PMID:
21252404
17.

[HLA-B*5701 and abacavir hypersensitivity reaction].

Servonnet A, Leclercq E, Delacour H, Ceppa F.

Pathol Biol (Paris). 2010 Dec;58(6):e95-100. doi: 10.1016/j.patbio.2008.12.001. Epub 2009 Feb 24. French.

PMID:
19243901
18.

Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil.

Crovella S, Biller L, Santos S, Salustiano A, Brandao L, Guimaraes R, Segat L, Lima Filho JL, Arraes LC.

Clinics (Sao Paulo). 2011;66(8):1485-8. No abstract available.

19.

Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.

Chen SJ, Yang SP, Hung CC, Fung CP.

AIDS. 2010 May 15;24(8):1238-9. doi: 10.1097/QAD.0b013e3283389e13. No abstract available.

PMID:
20421748
20.

In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.

Sanchez-Giron F, Carnevale A.

Pharmacogenomics. 2012 Feb;13(3):251-2. doi: 10.2217/pgs.11.169. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk